CLVS [NASD]
Clovis Oncology, Inc.
Index- P/E- EPS (ttm)-2.11 Insider Own0.40% Shs Outstand138.21M Perf Week-8.77%
Market Cap99.96M Forward P/E- EPS next Y-0.83 Insider Trans-14.24% Shs Float128.04M Perf Month-67.74%
Income-258.40M PEG- EPS next Q-0.41 Inst Own37.50% Short Float21.64% Perf Quarter-58.30%
Sales145.00M P/S0.69 EPS this Y47.70% Inst Trans-19.59% Short Ratio2.25 Perf Half Y-79.57%
Book/sh-2.19 P/B- EPS next Y39.70% ROA-51.60% Target Price3.00 Perf Year-86.24%
Cash/sh0.87 P/C0.82 EPS next 5Y- ROE101.90% 52W Range0.69 - 7.24 Perf YTD-73.69%
Dividend- P/FCF- EPS past 5Y24.10% ROI-67.70% 52W High-90.15% Beta1.79
Dividend %- Quick Ratio1.40 Sales past 5Y353.00% Gross Margin73.40% 52W Low2.62% ATR0.18
Employees413 Current Ratio1.50 Sales Q/Q-10.20% Oper. Margin- RSI (14)25.39 Volatility11.63% 14.19%
OptionableYes Debt/Eq- EPS Q/Q31.50% Profit Margin- Rel Volume0.36 Prev Close0.71
ShortableYes LT Debt/Eq- EarningsMay 04 BMO Payout- Avg Volume12.33M Price0.71
Recom3.20 SMA20-50.09% SMA50-59.84% SMA200-76.47% Volume4,401,362 Change-0.04%
May-06-22Downgrade H.C. Wainwright Buy → Neutral
May-18-20Reiterated H.C. Wainwright Buy $29 → $33
Apr-27-20Downgrade SVB Leerink Mkt Perform → Underperform $5
Apr-09-20Downgrade BofA/Merrill Neutral → Underperform $6
Jan-08-20Reiterated H.C. Wainwright Buy $36 → $27
Nov-19-19Downgrade Evercore ISI Outperform → In-line $8
Sep-24-19Downgrade SVB Leerink Outperform → Mkt Perform $22 → $10
Aug-13-19Downgrade BofA/Merrill Buy → Neutral
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-29-19Downgrade Goldman Neutral → Sell
Apr-15-19Reiterated H.C. Wainwright Buy $39 → $37
Feb-13-19Initiated H.C. Wainwright Buy $40
Dec-04-18Upgrade Leerink Partners Mkt Perform → Outperform
Oct-31-18Downgrade JP Morgan Overweight → Neutral
Oct-19-18Resumed Piper Jaffray Neutral
Sep-25-18Initiated Leerink Partners Mkt Perform
Feb-22-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Feb-22-18Upgrade Evercore ISI In-line → Outperform
Oct-23-17Initiated Barclays Overweight $105
Sep-15-17Initiated RBC Capital Mkts Sector Perform $81
May-16-22 08:30AM  
May-09-22 11:05AM  
May-06-22 01:23PM  
07:12AM  
May-05-22 10:22AM  
08:00AM  
May-04-22 02:21PM  
09:15AM  
08:00AM  
May-03-22 08:35AM  
May-02-22 12:21PM  
10:01AM  
Apr-28-22 08:00AM  
Apr-27-22 03:03PM  
Apr-20-22 08:00AM  
Apr-18-22 04:51PM  
Apr-08-22 02:54PM  
08:00AM  
Apr-04-22 03:11PM  
Mar-31-22 05:06PM  
04:41PM  
09:22AM  
08:01AM  
06:00AM  
Mar-25-22 11:30AM  
Mar-16-22 08:00AM  
Feb-26-22 06:34AM  
Feb-25-22 08:00AM  
Feb-24-22 02:49PM  
Feb-23-22 08:05AM  
Feb-10-22 04:05PM  
Jan-19-22 10:15AM  
Jan-10-22 08:00AM  
Jan-03-22 10:07AM  
Dec-09-21 08:00AM  
Dec-03-21 11:31AM  
Nov-04-21 06:46AM  
Nov-03-21 09:15AM  
08:00AM  
07:48AM  
Oct-27-21 03:03PM  
Oct-20-21 08:00AM  
Oct-19-21 08:00AM  
Oct-15-21 09:15AM  
Oct-07-21 09:00AM  
Sep-29-21 10:00AM  
Sep-20-21 08:00AM  
Sep-03-21 11:31AM  
Aug-27-21 11:37AM  
Aug-24-21 02:00AM  
Aug-16-21 04:21PM  
Aug-05-21 10:57AM  
02:34AM  
Aug-04-21 09:15AM  
08:00AM  
Jul-28-21 03:03PM  
Jul-21-21 08:00AM  
Jul-12-21 04:05PM  
Jun-28-21 07:00AM  
Jun-23-21 07:00AM  
Jun-15-21 05:39AM  
Jun-12-21 06:49AM  
Jun-10-21 04:30PM  
Jun-09-21 11:00AM  
06:36AM  
Jun-04-21 11:31AM  
May-19-21 06:27PM  
May-17-21 04:15PM  
May-07-21 03:09AM  
May-06-21 10:39AM  
May-05-21 10:04AM  
09:15AM  
08:00AM  
06:45AM  
Apr-28-21 04:05PM  
12:33PM  
Apr-21-21 04:00PM  
Apr-10-21 08:30AM  
Mar-25-21 11:30AM  
Mar-22-21 09:50AM  
08:34AM  
07:17AM  
Mar-19-21 04:30PM  
11:13AM  
09:24AM  
08:19AM  
08:00AM  
06:50AM  
Mar-02-21 10:21AM  
Feb-23-21 09:24AM  
08:00AM  
06:30AM  
Feb-22-21 10:14AM  
Feb-17-21 08:00AM  
Feb-11-21 08:00AM  
Feb-06-21 02:41AM  
Feb-04-21 08:00AM  
Feb-02-21 10:00AM  
Jan-11-21 08:00AM  
Dec-30-20 06:49AM  
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer. It is also developing lucitanib, an investigational angiogenesis inhibitor, which inhibits vascular endothelial growth factor receptors 1 through 3 (VEGFR 1-3), platelet-derived growth factor receptors alpha and beta (PDGFRa/), and fibroblast growth factor receptors 1 through 3 (FGFR 1-3); and FAP-2286, an investigational peptide-targeted radionuclide therapy and imaging agent targeting fibroblast activation protein. The company sells its Rubraca through a limited number of specialty distributor and specialty pharmacy providers, who subsequently sells Rubraca to patients and health care providers. Clovis Oncology, Inc. has license agreements with Pfizer Inc., AstraZeneca UK Limited, Advenchen Laboratories LLC, and 3B Pharmaceuticals GmbH, a clinical collaboration with Bristol Myers Squibb Company; and a partnership with Foundation Medicine, Inc. The company was incorporated in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MUEHL DANIEL WSee RemarksMay 02Sale1.974,5709,00285,439May 03 04:15 PM
IVERS-READ GILLIAN CSee RemarksMay 02Sale1.973,7337,353276,220May 03 04:15 PM
Gross Paul EdwardSee RemarksMay 02Sale1.974,5709,00279,393May 03 04:15 PM
Rolfe LindseySee RemarksMay 02Sale1.974,2528,37698,327May 03 04:15 PM
Harding Thomas C.See RemarksMay 02Sale1.97761502,936May 03 04:15 PM
Harding Thomas C.See RemarksMay 02Sale1.971,7003,34912,429May 03 04:15 PM
Harding Thomas C.See RemarksApr 04Sale2.667192,831Apr 05 04:16 PM
Gross Paul EdwardSee RemarksMar 02Sale1.8710,70619,97766,444Mar 03 04:15 PM
Rolfe LindseySee RemarksMar 02Sale1.8710,94520,42386,817Mar 03 04:15 PM
MUEHL DANIEL WSee RemarksMar 02Sale1.8710,70619,97772,490Mar 03 04:16 PM
Harding Thomas C.See RemarksMar 02Sale1.878801,6421,662Mar 03 04:15 PM
Harding Thomas C.See RemarksMar 02Sale1.876,94612,9616,850Mar 03 04:15 PM
IVERS-READ GILLIAN CSee RemarksMar 02Sale1.8710,77020,097264,308Mar 03 04:15 PM
Rolfe LindseySee RemarksFeb 02Sale1.944,5148,75684,357Feb 03 04:17 PM
MUEHL DANIEL WSee RemarksFeb 02Sale1.945,43610,54470,045Feb 03 04:15 PM
Harding Thomas C.See RemarksFeb 02Sale1.94811571,652Feb 03 04:15 PM
Harding Thomas C.See RemarksFeb 02Sale1.942,0373,9516,015Feb 03 04:15 PM
IVERS-READ GILLIAN CSee RemarksFeb 02Sale1.944,4428,616261,802Feb 03 04:16 PM
Gross Paul EdwardSee RemarksFeb 02Sale1.945,43610,54463,999Feb 03 04:15 PM
Harding Thomas C.See RemarksJan 03Sale2.757191,551Jan 04 04:15 PM
IVERS-READ GILLIAN CSee RemarksDec 02Sale3.00304912260,041Dec 03 04:15 PM
Harding Thomas C.See RemarksDec 02Sale3.007211,542Dec 03 04:15 PM
Harding Thomas C.See RemarksDec 02Sale3.001414235,395Dec 03 04:15 PM
MUEHL DANIEL WSee RemarksDec 02Sale3.0024874467,403Dec 03 04:16 PM
Rolfe LindseySee RemarksDec 02Sale3.003461,03882,628Dec 03 04:16 PM
Gross Paul EdwardSee RemarksDec 02Sale3.0024874461,357Dec 03 04:15 PM
Rolfe LindseySee RemarksNov 02Sale4.554,20919,15179,987Nov 03 04:18 PM
IVERS-READ GILLIAN CSee RemarksNov 02Sale4.553,69616,817257,074Nov 03 04:19 PM
Harding Thomas C.See RemarksNov 02Sale4.55622821,531Nov 03 04:15 PM
Harding Thomas C.See RemarksNov 02Sale4.551,6827,6534,346Nov 03 04:15 PM
MUEHL DANIEL WSee RemarksNov 02Sale4.554,52320,58064,505Nov 03 04:15 PM
Gross Paul EdwardSee RemarksNov 02Sale4.554,52320,58058,459Nov 03 04:15 PM
Harding Thomas C.See RemarksOct 04Sale4.416261,412Oct 05 04:31 PM
Harding Thomas C.See RemarksSep 02Sale4.897341,403Sep 03 05:21 PM
Harding Thomas C.See RemarksSep 02Sale4.891416893,563Sep 03 05:21 PM
IVERS-READ GILLIAN CSee RemarksSep 02Sale4.893041,487254,980Sep 03 04:15 PM
Rolfe LindseySee RemarksSep 02Sale4.893471,69778,122Sep 03 04:15 PM
Gross Paul EdwardSee RemarksSep 02Sale4.892491,21855,318Sep 03 04:15 PM
MUEHL DANIEL WSee RemarksSep 02Sale4.892491,21861,364Sep 03 04:16 PM
IVERS-READ GILLIAN CSee RemarksAug 03Sale4.823,68317,752252,005Aug 03 09:40 PM
Harding Thomas C.See RemarksAug 03Sale4.82622991,391Aug 03 09:38 PM
Harding Thomas C.See RemarksAug 03Sale4.821,6788,0882,511Aug 03 09:38 PM
MUEHL DANIEL WSee RemarksAug 03Sale4.824,50721,72458,459Aug 03 09:36 PM
Rolfe LindseySee RemarksAug 03Sale4.824,19520,22075,473Aug 03 09:32 PM
Gross Paul EdwardSee RemarksAug 03Sale4.824,50721,72452,413Aug 03 09:31 PM
Harding Thomas C.See RemarksJul 01Sale5.79261511,272Jul 06 04:16 PM
Gross Paul EdwardSee RemarksJun 03Sale5.632311,30149,262Jun 03 07:03 PM
MUEHL DANIEL WSee RemarksJun 03Sale5.632311,30155,308Jun 03 07:01 PM
Rolfe LindseySee RemarksJun 03Sale5.633221,81373,602Jun 03 07:00 PM
IVERS-READ GILLIAN CSee RemarksJun 03Sale5.632831,593249,905Jun 03 06:58 PM
Harding Thomas C.See RemarksJun 03Sale5.637391,235Jun 03 06:57 PM
Harding Thomas C.See RemarksJun 03Sale5.631317381,725Jun 03 06:57 PM